Skip to search formSkip to main contentSkip to account menu

gemcitabine/SU5416

Known as: dFdC/SU-5416 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Rationale: The pathogenesis of pulmonary arterial hypertension (PAH) involves remodelling of the pulmonary arteries, increased… 
2017
2017
Background: SUGEN/hypoxia (SuHx) causes pulmonary hypertension (PH) in rats. Cardiac MR (CMR) is the gold standard for… 
2016
2016
The SU5416 + hypoxia (SuHx) rat model is a commonly used model of severe pulmonary arterial hypertension. While it is known that… 
Review
2012
Review
2012
In spite of treatment, severe angioproliferative pulmonary arterial hypertension (PAH) remains a disease characterized by great… 
2011
2011
AIM To explore the effect of VEGF inhibitor SU5416 on podocytopathy of rats with type I diabetic nephropathy. METHODS Thirty… 
Review
2006
Review
2006
2005
2005
SummaryVascular endothelial growth factor (VEGF) is a potent stimulant of angiogenesis. SU5416, is a small molecule tyrosine… 
2000
2000
SU5416 [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1, 3-dihydro-indol-2-one], an inhibitor of VEGF (vascular endothelial growth…